Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87a863132c68cf0f62015bbd5d05ab38 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2318-20 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 |
filingDate |
2014-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94584350883ffc2adea9d87984844f1d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcd3f97b5383ba1629d34a5533d83a15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4ca730c0714ddce8eaff712a74604db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_151fc1d014c9083bf24cb69accc00c37 |
publicationDate |
2022-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20220136463-A |
titleOfInvention |
Cysteine engineered fibronectin type iii domain binding molecules |
abstract |
Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids have one or more amino acid residues to encode for a cysteine engineered FN3 domain containing monospecific or bispecific molecule. mutating the nucleic acid sequence of the parent molecule by replacing it with cysteine; expressing a cysteine engineered FN3 domain containing molecule; and recovering the cysteine engineered FN3 domain containing molecule. The isolated cysteine engineered monospecific or bispecific FN3 domain containing molecule can be covalently attached to a detection label or drug moiety and used therapeutically. . |
priorityDate |
2013-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |